This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Doherty, T. M.
Right arrow Articles by Coffman, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doherty, T. M.
Right arrow Articles by Coffman, R. L.

 Previous Article  |  Next Article 

J. Virol., 05 1997, 3702-3709, Vol 71, No. 5
Copyright © 1997, American Society for Microbiology

Modulation of murine AIDS-related pathology by concurrent antibody treatment and coinfection with Leishmania major

TM Doherty, N Giese, HC Morse 3rd and RL Coffman
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, USA.

Infection of C57BL/6 mice with a mixture of murine leukemia viruses (MuLVs) designated LP-BM5 MuLV leads to a disease characterized by progressive immunodeficiency and lymphoproliferation, known as murine AIDS (MAIDS). The development of MAIDS is associated with increased B- cell lymphoblast proliferation, but there is reason to believe that T- cell function and, particularly, T-cell-derived cytokines may also play a role. We have previously shown that concurrent infection with Leishmania major (which induces a strongly polarized Th1 response in C57BL/6 mice) and LP-BM5 MuLV modulates the disease induced by both infections. Here we show by treatment of mice with anticytokine antibodies that this modulation is largely exerted through the balance of Th1 and Th2 cytokines. Infected mice treated with antibodies to interleukin-4 and interleukin-10 exhibited a delayed development of MAIDS-related pathology and maintained T-cell responsiveness longer than mice treated with control antibody. Gamma interferon induced by coinfection with L. major synergized with anti-IL-4 treatment to inhibit the development of MAIDS pathology. Conversely, treatment with anti-gamma interferon led to a significant increase in splenomegaly and lymphadenopathy and slightly exacerbated loss of T-cell function. These data suggest that the production of Th2-associated cytokines may promote MAIDS pathology, while Th1-associated cytokines may help control the disease.


This article has been cited by other articles:

  • Umemura, M., Hirose, K., Wajjwalku, W., Nishimura, H., Matsuguchi, T., Gotoh, Y., Takahashi, M., Makino, M., Yoshikai, Y. (2001). Impaired IL-15 production associated with susceptibility of murine AIDS to mycobacterial infection. J. Leukoc. Biol. 69: 138-148 [Abstract] [Full Text]